Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Ribo Life Science Co., Ltd.
蘇州瑞博生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6938)

PROPOSED ADOPTION OF THE H SHARE OPTION SCHEME AND THE H SHARE INCENTIVE SCHEME

The board (the "**Board**") of directors (the "**Directors**") of Suzhou Ribo Life Science Co., Ltd. (the "**Company**") announces that on March 25, 2026, the Board has resolved to propose the adoption of the H share option scheme (the "**H Share Option Scheme**") and the H share incentive scheme (the "**H Share Incentive Scheme**", collectively the "**Share Schemes**") of the Company, subject to the approval of the shareholders of the Company (the "**Shareholders**").

The Share Schemes are designed to provide eligible persons (including employee participants, service providers and related entity participants) with the opportunity to acquire proprietary interests in the Company and to encourage eligible persons to work towards enhancing the value of the Company and the shares of the Company (the "**Shares**") for the benefit of the Company and Shareholders as a whole.

Both the H Share Option Scheme and the H Share Incentive Scheme constitute share schemes involving the issuance of new shares by the Company under Chapter 17 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). The provisions of the H Share Option Scheme and H Share Incentive Scheme will comply with Chapter 17 of the Listing Rules. No share options or share awards involving issuance of new Shares under the Share Schemes will be granted during the six months from January 9, 2026, the date on which H Shares were listed and on which dealings in the H Shares were first permitted to commence on the Stock Exchange. The adoption of the H Share Option Scheme and H Share Incentive Scheme are subject to, among other things, (i) the passing of special resolutions at the forthcoming annual general meeting of the Company (the "**AGM**") pursuant to the articles of association of the Company, and (ii) the granting of approval by the listing committee of the Stock Exchange for the listing of, and permission to deal in, any H Shares on the Stock Exchange which may fall to be issued and allotted pursuant to all the share options and shares awards to be granted under the Share Schemes. A circular of the Company containing, among other things, (i) further details of the H Share Option Scheme; (ii) further details of H Share Incentive Scheme; (iii) further details of the scheme limit and service provider sublimit; (iv) the proposed authorization to the Board and/or its delegate(s) to handle matters pertaining to the Share Schemes; and (v) a notice of the AGM, will be despatched to the Shareholders (if applicable) in accordance with the requirements of the Listing Rules in due course.

As of the date of this announcement, the H Share Option Scheme and H Share Incentive Scheme are subject to approval of the Shareholders. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, March 25, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.